12:00 AM
 | 
Apr 10, 2006
 |  BC Week In Review  |  Clinical News  |  Regulatory

ACTOplus met XR regulatory update

Takeda submitted an NDA for once-daily ACTOplus met XR, an extended-release version of ACTOplus met, to treat Type II diabetes. The application was submitted...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >